GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

ALYGLO, a blood product for treating immunodeficiency disorders developed by GC Biopharma Corp (Provided by GC Biopharma Corp) / News1
ALYGLO, a blood product for treating immunodeficiency disorders developed by GC Biopharma Corp (Provided by GC Biopharma Corp) / News1

Quarterly Sales by Product Category for GC Biopharma Corp (Unit: 100 million KRW)(Provided by GC Biopharma Corp) / News1
Quarterly Sales by Product Category for GC Biopharma Corp (Unit: 100 million KRW)(Provided by GC Biopharma Corp) / News1

© Copyright by News1. All Rights Reserved.